Ethnicity/race and outcome in the treatment of depression

Results from STAR*D

Ira M. Lesser, Daniel B. Castro, Bradley N. Gaynes, Jodi Gonzalez, A. John Rush, Jonathan E. Alpert, Madhukar Trivedi, James F. Luther, Stephen R. Wisniewski

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

OBJECTIVES: This secondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared rates of remission and response for blacks (n = 495), whites (n = 1853), and Hispanics (n = 327) with nonpsychotic major depressive disorder who were treated with citalopram. METHODS: STAR*D included representative outpatients treated in 23 psychiatric and 18 primary care centers. Participants received flexible doses of citalopram for up to 14 weeks, with dosage adjustments based on routine clinical assessments. Efforts were made to achieve remission, using a measurement-based care approach with adjustments based on symptoms and side effects assessed at each visit. RESULTS: There were significant differences among groups on many baseline demographic, sociocultural, and clinical variables. Blacks and Hispanics were more socially disadvantaged and had more comorbidity than whites. Before adjusting for differences, blacks had lower remission rates than whites, with Hispanics intermediate between the 2. After adjustments, remission rates for groups were not significantly different on the 17-item Hamilton Rating Scale for Depression (HRSD), but remained lower for blacks compared with whites with the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR). Blacks took longer to achieve remission or response, though this did not remain after adjusting for baseline differences. CONCLUSIONS: Overall, black and to a lesser extent Hispanic participants had a poorer response to citalopram. After adjusting for baseline differences, the remission rates seemed to be more similar on the HRSD, but remained worse for blacks on the QIDS-SR. We discuss the possible biologic and sociocultural factors that may underlie these findings.

Original languageEnglish (US)
Pages (from-to)1043-1051
Number of pages9
JournalMedical Care
Volume45
Issue number11
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Depression
Social Adjustment
Hispanic Americans
Citalopram
Self Report
Therapeutics
Equipment and Supplies
Major Depressive Disorder
Biological Factors
Vulnerable Populations
Psychiatry
Comorbidity
Primary Health Care
Outpatients
Demography

Keywords

  • Antidepressants
  • Citalopram
  • Depression
  • Ethnicity
  • Race
  • Treatment outcomes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Lesser, I. M., Castro, D. B., Gaynes, B. N., Gonzalez, J., Rush, A. J., Alpert, J. E., ... Wisniewski, S. R. (2007). Ethnicity/race and outcome in the treatment of depression: Results from STAR*D. Medical Care, 45(11), 1043-1051. https://doi.org/10.1097/MLR.0b013e3181271462

Ethnicity/race and outcome in the treatment of depression : Results from STAR*D. / Lesser, Ira M.; Castro, Daniel B.; Gaynes, Bradley N.; Gonzalez, Jodi; Rush, A. John; Alpert, Jonathan E.; Trivedi, Madhukar; Luther, James F.; Wisniewski, Stephen R.

In: Medical Care, Vol. 45, No. 11, 11.2007, p. 1043-1051.

Research output: Contribution to journalArticle

Lesser, IM, Castro, DB, Gaynes, BN, Gonzalez, J, Rush, AJ, Alpert, JE, Trivedi, M, Luther, JF & Wisniewski, SR 2007, 'Ethnicity/race and outcome in the treatment of depression: Results from STAR*D', Medical Care, vol. 45, no. 11, pp. 1043-1051. https://doi.org/10.1097/MLR.0b013e3181271462
Lesser, Ira M. ; Castro, Daniel B. ; Gaynes, Bradley N. ; Gonzalez, Jodi ; Rush, A. John ; Alpert, Jonathan E. ; Trivedi, Madhukar ; Luther, James F. ; Wisniewski, Stephen R. / Ethnicity/race and outcome in the treatment of depression : Results from STAR*D. In: Medical Care. 2007 ; Vol. 45, No. 11. pp. 1043-1051.
@article{d12fbd8f29414b78bf16b918c139408b,
title = "Ethnicity/race and outcome in the treatment of depression: Results from STAR*D",
abstract = "OBJECTIVES: This secondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared rates of remission and response for blacks (n = 495), whites (n = 1853), and Hispanics (n = 327) with nonpsychotic major depressive disorder who were treated with citalopram. METHODS: STAR*D included representative outpatients treated in 23 psychiatric and 18 primary care centers. Participants received flexible doses of citalopram for up to 14 weeks, with dosage adjustments based on routine clinical assessments. Efforts were made to achieve remission, using a measurement-based care approach with adjustments based on symptoms and side effects assessed at each visit. RESULTS: There were significant differences among groups on many baseline demographic, sociocultural, and clinical variables. Blacks and Hispanics were more socially disadvantaged and had more comorbidity than whites. Before adjusting for differences, blacks had lower remission rates than whites, with Hispanics intermediate between the 2. After adjustments, remission rates for groups were not significantly different on the 17-item Hamilton Rating Scale for Depression (HRSD), but remained lower for blacks compared with whites with the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR). Blacks took longer to achieve remission or response, though this did not remain after adjusting for baseline differences. CONCLUSIONS: Overall, black and to a lesser extent Hispanic participants had a poorer response to citalopram. After adjusting for baseline differences, the remission rates seemed to be more similar on the HRSD, but remained worse for blacks on the QIDS-SR. We discuss the possible biologic and sociocultural factors that may underlie these findings.",
keywords = "Antidepressants, Citalopram, Depression, Ethnicity, Race, Treatment outcomes",
author = "Lesser, {Ira M.} and Castro, {Daniel B.} and Gaynes, {Bradley N.} and Jodi Gonzalez and Rush, {A. John} and Alpert, {Jonathan E.} and Madhukar Trivedi and Luther, {James F.} and Wisniewski, {Stephen R.}",
year = "2007",
month = "11",
doi = "10.1097/MLR.0b013e3181271462",
language = "English (US)",
volume = "45",
pages = "1043--1051",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Ethnicity/race and outcome in the treatment of depression

T2 - Results from STAR*D

AU - Lesser, Ira M.

AU - Castro, Daniel B.

AU - Gaynes, Bradley N.

AU - Gonzalez, Jodi

AU - Rush, A. John

AU - Alpert, Jonathan E.

AU - Trivedi, Madhukar

AU - Luther, James F.

AU - Wisniewski, Stephen R.

PY - 2007/11

Y1 - 2007/11

N2 - OBJECTIVES: This secondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared rates of remission and response for blacks (n = 495), whites (n = 1853), and Hispanics (n = 327) with nonpsychotic major depressive disorder who were treated with citalopram. METHODS: STAR*D included representative outpatients treated in 23 psychiatric and 18 primary care centers. Participants received flexible doses of citalopram for up to 14 weeks, with dosage adjustments based on routine clinical assessments. Efforts were made to achieve remission, using a measurement-based care approach with adjustments based on symptoms and side effects assessed at each visit. RESULTS: There were significant differences among groups on many baseline demographic, sociocultural, and clinical variables. Blacks and Hispanics were more socially disadvantaged and had more comorbidity than whites. Before adjusting for differences, blacks had lower remission rates than whites, with Hispanics intermediate between the 2. After adjustments, remission rates for groups were not significantly different on the 17-item Hamilton Rating Scale for Depression (HRSD), but remained lower for blacks compared with whites with the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR). Blacks took longer to achieve remission or response, though this did not remain after adjusting for baseline differences. CONCLUSIONS: Overall, black and to a lesser extent Hispanic participants had a poorer response to citalopram. After adjusting for baseline differences, the remission rates seemed to be more similar on the HRSD, but remained worse for blacks on the QIDS-SR. We discuss the possible biologic and sociocultural factors that may underlie these findings.

AB - OBJECTIVES: This secondary analysis of data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study compared rates of remission and response for blacks (n = 495), whites (n = 1853), and Hispanics (n = 327) with nonpsychotic major depressive disorder who were treated with citalopram. METHODS: STAR*D included representative outpatients treated in 23 psychiatric and 18 primary care centers. Participants received flexible doses of citalopram for up to 14 weeks, with dosage adjustments based on routine clinical assessments. Efforts were made to achieve remission, using a measurement-based care approach with adjustments based on symptoms and side effects assessed at each visit. RESULTS: There were significant differences among groups on many baseline demographic, sociocultural, and clinical variables. Blacks and Hispanics were more socially disadvantaged and had more comorbidity than whites. Before adjusting for differences, blacks had lower remission rates than whites, with Hispanics intermediate between the 2. After adjustments, remission rates for groups were not significantly different on the 17-item Hamilton Rating Scale for Depression (HRSD), but remained lower for blacks compared with whites with the 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR). Blacks took longer to achieve remission or response, though this did not remain after adjusting for baseline differences. CONCLUSIONS: Overall, black and to a lesser extent Hispanic participants had a poorer response to citalopram. After adjusting for baseline differences, the remission rates seemed to be more similar on the HRSD, but remained worse for blacks on the QIDS-SR. We discuss the possible biologic and sociocultural factors that may underlie these findings.

KW - Antidepressants

KW - Citalopram

KW - Depression

KW - Ethnicity

KW - Race

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=37349041002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349041002&partnerID=8YFLogxK

U2 - 10.1097/MLR.0b013e3181271462

DO - 10.1097/MLR.0b013e3181271462

M3 - Article

VL - 45

SP - 1043

EP - 1051

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 11

ER -